A Randomized, Double Blind, Comparative, Phase II/III Study to Evaluate the Immunogenicity and Safety of Three Formulations [15 mcg (unadjuvanted), 7.5 mcg (adjuvanted) and 3.75 mcg (adjuvanted)] of Monovalent H1N1 Influenza A (2009) Virus Vaccine, Manufactured by Panacea Biotec Ltd., in Healthy Pediatric Population 3 - 9 Years of Age.

Trial Profile

A Randomized, Double Blind, Comparative, Phase II/III Study to Evaluate the Immunogenicity and Safety of Three Formulations [15 mcg (unadjuvanted), 7.5 mcg (adjuvanted) and 3.75 mcg (adjuvanted)] of Monovalent H1N1 Influenza A (2009) Virus Vaccine, Manufactured by Panacea Biotec Ltd., in Healthy Pediatric Population 3 - 9 Years of Age.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 03 Mar 2011

At a glance

  • Drugs Adjuvants; Influenza A virus vaccine-H1N1
  • Indications Influenza A virus H1N1 subtype
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Panacea Biotec
  • Most Recent Events

    No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top